InMed Pharmaceuticals annual gross margin
2022
2023
2024
2025
InMed Pharmaceuticals's gross margin was 34.53% for fiscal 2025.
View full InMed Pharmaceuticals company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-06-30 | 34.53% | +10.58 pp |
| 2024 | 2024-06-30 | 23.94% | −78.78 pp |
| 2023 | 2023-06-30 | 102.73% | +62.93 pp |
| 2022 | 2022-06-30 | 39.80% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2025-12-31 | 22.46% | −19.00 pp |
| Q1 2026 | 2025-09-30 | 35.99% | −3.02 pp |
| Q4 2025 | 2025-06-30 | 44.20% | +7.87 pp |
| Q3 2025 | 2025-03-31 | 13.92% | −10.76 pp |
| Q2 2025 | 2024-12-31 | 41.46% | +15.32 pp |
| Q1 2025 | 2024-09-30 | 39.02% | +36.66 pp |
| Q4 2024 | 2024-06-30 | 36.32% | +17.71 pp |
| Q3 2024 | 2024-03-31 | 24.69% | −3.23 pp |
| Q2 2024 | 2023-12-31 | 26.14% | +179.20 pp |
| Q1 2024 | 2023-09-30 | 2.36% | −56.52 pp |
| Q3 2023 | 2023-03-31 | 18.62% | −23.46 pp |
| Q2 2023 | 2022-12-31 | 27.92% | — |
| Q1 2023 | 2022-09-30 | −153.07% | — |
| Q3 2022 | 2022-03-31 | 58.88% | — |
| Q2 2022 | 2021-12-31 | 42.08% | — |
Across the available reported history, InMed Pharmaceuticals's gross margin increased from 23.94% to 34.53%, a change of +10.58 percentage points. The latest reported quarter, Q2 2026, shows 22.46%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review InMed Pharmaceuticals filings at SEC.gov ↗